Evicenter
MarkdownMedical informationP&T meetings
Cretostimogene grenadenorepvec (CG0070)

BCG-unresponsive high-risk non-muscle-invasive bladder cancer

Manufacturer
CG Oncology
Launch
Not announced
Last updated
161 sources

Product information and disease descriptionPlace of product in therapyApproaches to treatmentCurrent treatment options and standard of care

Intravesical drug-releasing systems

10 evidence topics · 4 sources

SunRISe-1 Cohort 2: efficacy in the prescribing information
EndpointGemcitabine intravesical system
Participants“N=83”
Complete response rate (95% CI)“82% (72, 90)”
Duration of response, range in months“0+, 44+”
Duration of response ≥12 months, % (n)“51% (35)”
Basis of duration of response“Based on patients (n=68) with a complete response at any time”